What monitoring is required, what symptoms should prompt a call, and when will treatment be stopped
But the way the vitamin is administered can make a real difference in how your body uses it
Phase I Safety Trial: As noted, a Phase I trial (the first step in testing a drug in humans, usually focused on safety and pharmacokinetics) was registered in 2015, aiming to give BPC-157 to healthy volunteers
In vitro tendon-explant work found BPC-157 significantly increased fibroblast outgrowth, survival under oxidative stress, and migration in a dose-dependent manner, an effect linked to increased phosphorylation of FAK and paxillin Chang et al
That same body of work fed into an early-phase human trial registration (NCT02637284) that was later withdrawn before results were reported, which is why anyone telling you BPC-157 is "clinically proven" in humans is overstating the record